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ABSTRACT  
Aims To determine the effectiveness and safety of varenicline in treating tobacco dependence 
in patients with severe mental illness.  
Design A systematic review and meta-analysis of randomised controlled trials that compared 
varenicline with a placebo or an alternative intervention for smoking cessation or reduction. 
Setting Both in-patient and out-patient settings in any country.  
Participants Adult patients aged 18 and over with any type of severe mental illness.  The 
systematic review included eight studies comprising 398 participants.  
Measures Primary outcome measures were (1) smoking cessation (2) smoking reduction 
measured by changes in the number of cigarettes smoked per day and (3) number of 
psychiatric adverse events, which were collected at the end of treatment.  
Findings  The random-effect pooled estimates from the five studies that reported smoking 
related outcomes found that varenicline is statistically superior to placebo in smoking 
cessation (risk ratios 4.33; 95% CI: 1.96-9.56), and smoking reduction was higher in 
varenicline groups (mean reduced daily cigarettes was 6.39; 95% CI: 2.22-10.56). There is no 
significant difference regarding neuropsychiatric and other adverse events.  
Conclusions Varenicline appears to be significantly more effective than placebo in assisting 
with smoking cessation and reduction in people with severe mental illness. There appears to 
be no clear evidence that varenicline was associated with an increased risk of 
neuropsychiatric or other adverse events compared with placebo.   
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INTRODUCTION 
 
Smoking is one of the leading causes of preventable mortality, morbidity, and health 
inequality throughout the world [1]. Smoking prevalence is substantially higher in people 
with mental disorders, and the likelihood that an individual smokes is positively associated 
with the severity of the disorder [2,3]. Previous studies have reported that the severe mental 
illness (SMI) population has a smoking prevalence that is about three times greater than the 
rate observed in the general population, with estimates ranging from 40% to 88% among 
people with schizophrenia, and 50% to 70% among those with bipolar disorder [1,4-7]. In 
this review, SMI is defined as any non-organic disorder with psychotic features that result in 
a substantial disability, including schizophrenia or other types of schizophrenia-like 
psychosis (e.g. schizophreniform and schizoaffective disorders), bipolar disorder, or 
delusional disorder, corresponding to the ICD-10 categories [8]. 
  
People with SMI also tend to smoke more heavily than smokers without a diagnosed 
mental disorder [9-11]. The 2007 US National Health Interview reported a prevalence of 
heavy smoking (defined as those smoking more than 25 cigarettes a day) of 10.3% among 
those without a mental disorder, 15.1% in people with bipolar disorder and 17.8% in those 
with schizophrenia [12].  
 
High levels of nicotine dependence put smokers with SMI at increased risk of 
smoking-related mortality and morbidity [4,13,14]. A recent study reported that adult 
smokers with schizophrenia had a 145% higher risk of mortality from smoking-related 
diseases, such as lung cancer, cardiovascular diseases and chronic obstructive pulmonary 
disease (COPD), than non-smokers [15]. Smokers diagnosed with bipolar disorder also had a 
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57% higher risk of smoking-related mortality compared with non-smokers [15]. Given that 
SMI patients already have a shortened life expectancy, smoking cessation or reduction offers 
substantial potential benefits [16]. 
 
Tobacco use among individuals with SMI is financially costly to both themselves and 
society due to the cost of treatment of smoking-related diseases. It has been estimated that 
smokers with SMI spend nearly one-third of their monthly income on cigarettes, thus leaving 
less available for essentials such as food and housing [17]. The economic burden of smoking-
related diseases on society is considerable; in the UK the cost to the NHS of treating 
smoking-related diseases in the SMI population has been estimated at £719 million per 
annum [18]. 
  
Smokers with severe mental illness are just as likely to want to quit as people without 
mental disorders [19]. However, due to high levels of tobacco dependence, it is less likely 
that SMI patients will be successful in their attempts to stop smoking than individuals without 
mental disorders [1,5,20,21]. Smoking cessation rates in people with schizophrenia are less 
than half of those reported for smokers in the general population [22]. For many smokers 
with SMI who cannot quit smoking in the short-term, cutting down their consumption can be 
a transitional goal before they finally quit. There is evidence to suggest that, while smokers 
who reduce their cigarettes consumption should be advised to stop smoking, if they are 
unable to do so in the short-term, reducing the amount that they smoke can be helpful in 
increasing their likelihood of quitting [23-25]. Meanwhile, these patients will benefit from 
smoking reduction because they will ingest lower quantities of toxins from smoking 
cigarettes.  
 
 5 
 
This article is protected by copyright. All rights reserved. 
9DUHQLFOLQHLVDQLFRWLQLFDFHW\OFKROLQHĮȕUHFHSWRUSDUWLDODJRQLVWDQGDQĮIXOO
agonist [2]. As a recent pharmacological treatment, varenicline is expected to provide better 
effects than existing cessation pharmacotherapies. A recent network meta-analysis, which 
pooled the results of 12 Cochrane reviews, reported that varenicline significantly increased 
the odds of smoking cessation in the general population, compared to a placebo (Odds ratio 
(OR): 2.88, 95% CI 2.40 to 3.47). It is also superior to bupropion (OR: 1.59, 95% CI 1.29 to 
1.96) and to any single form of nicotine replacement therapy (NRT; OR 1.57, 95% CI 1.29 to 
1.91) in cessation trials [26]. 
 
However, safety concerns were raised when clinicians believed that they noted 
potential association of varenicline with serious neuropsychiatric symptoms in the general 
population. The U.S. Food and Drug Administration then issued a black box warning for 
varenicline regarding neuropsychiatric events in 2009 [27]. The adverse neuropsychiatric 
effects reported in patients taking varenicline include depression, hostility, aggression, 
psychosis, thoughts of self-harm, suicide and suicidal behaviour, erratic behaviour, and 
drowsiness.  
 
Because individuals with SMI are often excluded from large-scale studies of smoking 
cessation and smoking reduction, the available evidence on the use of varenicline in this 
population is limited. The aim of this review was to review the existing literature on the use 
of varenicline in patients with SMI for smoking cessation or reduction to determine the 
safety, tolerance, and efficacy of varenicline for treating tobacco dependence. The primary 
objectives of this review were: (1) to examine the effectiveness of varenicline compared with 
a placebo or an alternative intervention on smoking cessation, (2) on smoking reduction, and 
(3) to assess the risk of psychiatric adverse events of varenicline in people with SMI. This 
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review extends and updates a previous review of the effectiveness of smoking cessation 
interventions in people with severe mental illness before the launch of varenicline [28], and 
reviews of schizophrenia patients only [29,30]. To our knowledge, this is the first systematic 
review of trial-based studies on varenicline in populations with SMI. 
METHOD 
Data sources and searches 
A systematic review was undertaken, using established methods and following the Cochrane 
Handbook for Systematic Reviews and the NHS Centre for Reviews and Dissemination 
(CRD) guidelines [31,32]. We searched MEDLINE, EMBASE, PsycINFO, CINAHL and the 
Cochrane Library in September 2015. We considered randomised controlled trials (RCTs) 
without language restriction. We searched the reference lists of identified trials and review 
articles for additional trials. A bibliographical database, created using EndNote X7, was used 
to store and manage the retrieved references. An example of the search strategy is given in 
Appendix 1. 
Study selection 
Two authors (QW & SP) independently reviewed literature searches to identify relevant trials 
that met the inclusion criteria. We included both blinded and unblended  randomised 
controlled trials and quasi-randomised controlled trials that compared varenicline to a 
placebo or an alternative pharmacotherapy, for smoking cessation or reduction in adult 
patients aged 18 and over with any type of severe mental illness. We included both in-patient 
and out-patient settings in any country.  
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Primary Outcomes 
The primary outcome measures of interest were (1) smoking cessation in terms of quit rate, 
(2) smoking reduction measured by changes in the number of cigarettes smoked per day 
(CPD) at the end of treatment and (3) the safety of varenicline measured by  number of 
psychiatric adverse events in people with SMI.  
Data extraction and quality assessment 
Two reviewers conducted data extraction independently, using a standardised pre-piloted 
form. Extracted data consisted of study characteristics, patient characteristics, type of mental 
illness, varenicline dose, duration of the treatment, length of follow-up, smoking cessation 
and reduction outcome and also any adverse events recorded alongside the studies.  
Studies meeting the inclusion criteria were evaluated by two independent reviewers 
for their methodological rigour and quality, using quality assessment criteria adapted from 
the Cochrane risk of bias [31] and Centre for Reviews and Dissemination (CRD) guidance 
[32]. The modified tool that was developed for the purpose of this review enables the 
assessment of potential risk of bias, classifying them into three categories (low, high or 
unclear) depending on six aspects: study design, randomisation, blinding, data collection, 
confounders and outcome reporting. Any discrepancies were resolved by discussion between 
reviewers. 
Data synthesis and analysis  
We conducted meta-analyses following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines [33]. For dichotomous outcomes, we 
summarised the results of each study as a risk ratio (RR). For outcomes measured using 
continuous variables, such as number of cigarettes smoked per day, the preferred outcome 
was the difference between the average changes from the baseline. Combined overall effect 
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sizes were calculated using random effect models. Heterogeneity was quantified by the I2 
statistic, where ,ZDVFRQVLGHUHGHYLGHQFHRIVXEVWDQWLDOKHWHURJHQHLW\ [34]. Forest 
plots were displayed for the meta-analyses, showing individual study effect measures with 
95% confidence intervals (CIs), and the overall pooled estimate [35]. Authors were contacted 
if the results of interest were not reported. For studies that did not report CPD measurements, 
if expired carbon monoxide (CO) levels were reported, the relevant CO data were converted 
into cigarette consumption, based on the findings of a previous study [36]. All analyses were 
conducted with Stata version 13.0 (StataCorp, College Station, Texas). Statistical significance 
was accepted at p < 0.05 in each of the analyses.  
RESULTS 
Included studies 
The search identified a total of 176 relevant studies. Following removal of 64 duplicates, 101 
references were excluded based on title and abstract. Full-text assessments of the remaining 
11 potentially relevant articles excluded a further three studies [37-39]. A total of eight 
studies (398 participants) met the selection criteria and were included in the analysis [40-47]. 
Figure 1 describes the screening process. 
 
The included studies were published between 2011 and 2014. The majority of the 
trials included patients with schizophrenia or schizoaffective disorder, with only two studies 
investigating populations with bipolar disorder [40,47]. The trials tended to be small in size 
(ranging from 5 to 127 participants) compared with smoking cessation trials conducted in the 
general population [48]. Most were conducted in the United States and none were conducted 
in the UK. Table 1 summarises the characteristics of the included studies. 
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The selected randomised trials all compared varenicline with placebo. Three studies 
explored the effectiveness of varenicline alone, and the remaining studies evaluated 
varenicline in combination with individual behavioural interventions [42,44,47]. The duration 
of the varenicline treatment varied between eight and twelve weeks, and 81% of participants 
treated with varenicline completed the treatment, compared with 82% in placebo groups.  
 
Effectiveness of the interventions 
Four trials, with a total of 240 participants, reported smoking abstinence rates after 12 weeks 
of treatment with varenicline [40,42,45,46]. The pooled results (Figure 2) show that 
participants using varenicline were more than four times more likely to abstain from smoking 
at the end of the treatment than the placebo groups (RR 4.33, 95% CI 1.96 to 9.56, I² = 0%, 
p=0.910). The non-significance of the test for heterogeneity suggests that the differences 
between the studies are explicable by random variation.  
 
In addition, the effectiveness of varenicline was assessed in terms of reduction in CPD 
(i.e. the number of cigarettes smoked at the end of treatment minus the number smoked at 
baseline). A random effects meta-analysis of reduction in CPD was performed to estimate the 
effects of varenicline compared with placebo in terms of smoking reduction. The pooled 
reduction in smoking at the end of the treatment was significant and favoured varenicline 
(Figure 3). The weighted mean difference in smoking reduction was 6.39 (95% CI: 2.22-
10.56); i.e., smoking was reduced in the varenicline group by 6.39 more cigarettes per day 
than in the placebo group. But there was substantial heterogeneity among trials (I² = 89.2%, 
p<0.001), this is largely due to one trial in which smoking reduction was much higher in the 
varenicline group than the placebo group [45]. 
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Assessments of psychiatric symptoms and safety  
Most of the selected studies reported mental health outcomes and other relevant adverse 
effects of varenicline in people with severe mental illness. We first examined the outcomes of 
suicidal ideation, depressed mood, and anxiety, which form the basis for the black box 
warning on varenicline. Figure 4 shows the pooled relative risk of these neuropsychiatric 
effects, comparing varenicline to placebo. There were no significant differences between 
varenicline and placebo in terms of suicidal ideation, depressed mood, or anxiety. However, 
the numbers of participants in these studies were low, with the largest study having 127 
participants. Therefore, these results should be interpreted with caution. Not all of the studies 
included in this review gave a detailed breakdown of adverse events, and it may be that some 
adverse events were not reported. It may also be the case that participants who were lost to 
follow-up experienced an adverse event that was not reported to the study team. Therefore, it 
is possible that not all adverse events were captured.  
 
Table 2 summarises other adverse effects reported in both the treatment and control groups of 
the selected studies. The pooled relative risks across studies were reported with 
corresponding 95% confidence intervals. The most commonly reported adverse effects were 
nausea, insomnia, abnormal dreams, and fatigue. However, none of the summary estimates 
showed a significant treatment effect.  
DISCUSSION 
In this review, a total of eight trials, with 398 eligible participants, published after 2011, were 
assessed to examine the incremental effect of varenicline, compared with placebo, in people 
with SMI. The pooled results of the meta-analysis suggest varenicline had a favourable effect 
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on smoking cessation, compared with placebo in people with SMI (RR 4.33, 95% CI: 1.96-
9.56; OR 6.16, 95% CI: 2.47-15.36). In a recent Cochrane systematic review, Cahill and 
colleagues conducted a meta-analysis of 14 trials and found varenicline was more effective 
than placebo in smoking cessation for the general population (OR 2.88; 95% CI 2.40 to 3.47) 
[26]. The increase in the odds of quitting smoking when using varenicline, compared with 
placebo, is greater for people with SMI than for the general. 
 
With many reviews of smoking cessation interventions, the measurement of quit rates 
varies amongst the studies. In this review, most studies defined smoking cessation using 
seven-day point prevalence abstinence at the end of treatment validated by expired CO (i.e. a 
self-reported 0 cigarettes smoked in the preceding 7 days confirmed by expired CO level of 
less than 10 ppm).  One study defined quit as expired CO level less than 10 ppm at each of 
the last 4 visits [45]DQGRQHVWXG\GLGQ¶WVSHFLI\KRZWKH\GHILQHVPRNing cessation [42]. 
However, none of the studies reported a prolonged abstinence measure (i.e., sustained 
abstinence for at least six months period) [49]. This suggests the need for assessing prolonged 
smoking abstinence of smoking cessation interventions in this population. 
 
The primary outcome in this review is smoking cessation at the end of treatment 
which ranged from 8 to 14 weeks. Follow-up was not clearly reported or achieved in most of 
the selected studies and only two studies gave results in quit rates at six-month follow-up. In 
one trial [40], 60% of those who quit after 12 weeks on varenicline had relapsed by the end of 
six months, compared to 33% of those in the control group. The other study [46] reported a 
relapse rate of 38% in the varenicline group and a 50% relapse rate in the placebo group at 
six-month follow-up. This demonstrates that people with SMI who try to quit smoking 
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relapse easily and more research is needed into relapse prevention interventions for smoking 
cessation in people with SMI. 
 
In the general population, the standard approach to smoking cessation is to quit 
abruptly on a designated quit day [50]. However, cutting down on smoking through harm 
reduction strategies can be an alternative method of managing smoking, given the greater 
degree of addiction in the SMI population [5,20,21].  Smoking reduction yields substantial 
benefits by reducing the toxic intake from smoking, reducing the relative risk of smoking-
related diseases, and increasing the likelihood of definitively quitting in the future [51].  
 
The results of our meta-analysis suggest that varenicline significantly reduced 
smoking in people with SMI, compared with placebo. Given that estimates of the rate of 
quitting vary markedly among studies, in terms of length of time quit, length of follow-up, 
and means of measurement, the use of changes in daily cigarette consumption as a 
measurement of smoking behaviour change facilitates direct comparison across studies. 
Patients in placebo groups reported a reduction in cigarettes per day of 26.9% from baseline, 
while people treated with varenicline achieved a weighted average CPD reduction of 49.4% 
from baseline across the studies. Varenicline yielded an additional CPD reduction of 6.39 
(95% CI: 2.22-10.56) at the end of treatment, compared with placebo. This indicates that 
varenicline is an efficacious aid for smoking reduction in people with SMI.  
 
Smokers with severe mental disorders smoke more heavily than the general 
population [1]. Smokers with SMI included in this review smoked an average of 20.0 (S.D. = 
4.9) cigarettes per day with a mean Fagerstrom Test for Nicotine Dependence (FTND) score 
as high as 5.9 (S.D. = 0.6). The average number of cigarettes smoked per day by adult 
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smokers was 12.7 in England in 2010 [52]. This indicates that smokers with SMI smoked 
almost twice as much as those without SMI, and most are heavy smokers (defined as those 
smoking more than 20 cigarettes a day) [53]. 
Smoking-related medical illness is the one of the primary causes of morbidity and 
mortality in SMI patients. Smoking-related comorbidities are associated with higher 
proportions of heavy smoking [4], and the greater the number of cigarettes smoked daily, the 
higher the risk of smoking-related diseases and mortality [13,15,54]. Therefore, smoking 
reduction is expected to generate health benefits for these smokers, even if they are not ready 
to, or cannot, quit smoking in the short term. 
 
Varenicline is a worthwhile aid to smoking cessation and smoking reduction in people 
with SMI. However, the safety and risk of neuropsychiatric side effects of varenicline has 
been debated in literature, thus far without resolution. Some epidemiological studies report an 
increased risk of adverse psychiatric events associated with varenicline use. For example, the 
UK Medicines and Healthcare Products Regulatory Agency (MHRA) Yellow Card reports 
state that varenicline had the highest reported rate of depression disorders, and the second-
highest rate of non-fatal suicidal behaviour compared with other drugs in the MHRA study 
[55]. 6LPLODUO\0RRUHDQGFROOHDJXHVVWXGLHGWKH)'$¶V$GYHUVH(YHQW5HSRUWLQJ6\VWHP
(AERS) database from 1998 to September 2010 and found that varenicline substantially 
increased the risk of reported depression and suicidal/self-injurious behaviour [27]. 
 
On the other hand, results from many randomised clinical trials and reviews of trials 
arrive at a different conclusion. Although higher frequencies of neuropsychiatric side effects 
have been reported for varenicline in many studies, randomised controlled trials have not 
shown evidence of an elevated risk when compared with placebo or other smoking cessation 
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medications [48,56-62]. A recent meta-analysis of 39 randomised controlled trials found no 
increased risk of suicide or attempted suicide, suicidal ideation, depression, or death in 
varenicline users when compared with placebo groups in the general population [62]. 
Amongst the studies included in this review, a majority of studies reported no significant 
difference between varenicline and control groups in terms of neuropsychiatric events in 
people with SMIs [40-42,44-45,47]. Only one study reported a significantly increased risk of 
suicidal ideation in the varenicline group (one case) compared with the placebo group (no 
cases) [43]. The pooled meta-analysis results show no significant difference in suicidal 
ideation, depression, and anxiety between varenicline and placebo by the end of the 
treatment.   
 
Other side effects such as nausea, insomnia, and abnormal dreams were common in 
both treatment and placebo groups. The overall pooled results showed no significant 
difference between treatment groups. It is unclear whether some of the adverse reactions to 
varenicline were partly caused by nicotine withdrawal symptoms. Nicotine in cigarettes is an 
addictive drug, and nicotine withdrawal produces a wide range of withdrawal symptoms such 
as headaches, nausea, anxiety, and depression. Previous smoking cessation studies have 
reported similar symptoms among smokers treated with bupropion, as well as with other 
nicotine replacement therapies [20,27]. 
 
The target population in this review is patients with severe mental illness, namely, 
patients with schizophrenia or bipolar disorder. For people with psychiatric illnesses, 
interpretation of neuropsychiatric events may differ from that of the general population. For 
example, one study reported lifetime suicidal ideation and behaviour rates among recruited 
patients of 96.8% in the varenicline group and 82.8% in the placebo group [40]. This may 
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affect the incidence of neuropsychiatric adverse events reported in the trials. However, there 
is no definitive evidence of the exacerbation of psychiatric symptoms, psychosis, depression 
or suicidality using varenicline among people with SMI [57,58,64]. The pooled results of this 
review found no significant difference in neuropsychiatric or other adverse events in people 
with SMI between varenicline and placebo groups. But the systematic review used only data 
extracted from RCTs and these may not capture all possible adverse events due to exclusion 
criteria, i.e. trials only included clinically stable patients. It is important for practitioners to 
monitor patients closely for neuropsychiatric adverse events during varenicline treatment. 
Future studies with larger samples are needed to explore the relationship between varenicline 
and adverse psychiatric events 
 
 
  7KH&DKLOO¶VUHYLHZIRXQGYDUHQLFOLQHLQFUHDVHGWKHFKDQFHVRITXLWWLQJ smoking 
compared with placebo, single NRT and bupropion in the general population, but there was 
no significant difference in smoking cessation between varenicline and combination NRT 
groups [26]. In this review, all eight trials compared varenicline with placebo in treating 
tobacco dependence in people with SMI. Given that combination NRT and bupropion are 
UHFRPPHQGHGE\1,&(JXLGDQFHRQµ6PRNLQJDFXWHPDWHUQLW\DQGPHQWDOKHDOWKVHUYLFHV¶
and are widely used in prescriptions of stop smoking pharmacotherapies, further studies that 
compare varenicline with combination NRT and bupropion in people with SMI are 
recommended [65].  
Current varenicline trials in SMI patients tend to use monotherapy, with only a few 
studies appending behavioural components such as financial incentives or brief advice. There 
is evidence that, in highly addicted smokers, a combination of treatment such as varenicline 
combined with bupropion may improve smoking cessation rates. Therefore, such a 
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combination of treatments is worthy of consideration, given the high level of addiction in 
patients with SMI [66]. Smokers should be encouraged to use behavioural interventions and 
pharmacotherapy, since a combination of the two has been proven to be more effective than 
either intervention alone [67]. 
 
Study limitations  
To our knowledge, this is the first systematic review of trial-based studies of varenicline in 
populations with severe mental illness. However, our study has some limitations. First, the 
included trials tend to be small in size (ranging from 5 to 127 patients). This is because 
people with severe mental illness are often excluded from large clinical trials, and in those 
studies that targeted SMI patients, the recruitment rates were normally very low. Second, the 
follow-up periods in all the studies were short, 8 to 12 weeks in most cases, with only two 
trials reporting a follow-up assessment at 24 weeks. Third, all eight studies in this review 
include only clinically stable adult patients diagnosed with SMI. This is a potential source of 
bias and further research is needed to explore how far findings of this review can be 
generalised to clinically unstable SMI patients. 
CONCLUSION  
 
People with SMI are more likely to smoke and smoke more heavily, than the general 
population. SmoNLQJKDUPVSDWLHQWV¶SK\VLFDODQGPHQWDOKHDOWKDQGLQFUHDVHVWKHLUILQDQFLDO
burden, especially given that many of these patients are in poor physical health and live on 
government benefits. Smoking-related medical illness is the one of the primary causes of 
morbidity and mortality in SMI patients; therefore, the development of a safe and effective 
treatment for smoking dependence is crucial. 
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In this systematic review, we identified and analysed eight clinical trials that studied 
the effectiveness of varenicline as an aid to smoking cessation and reduction in people with 
severe mental illness. The random-effect pooled estimates from the five studies that reported 
smoking related outcomes showed that, at the end of treatment, varenicline increased the 
chances of successful smoking cessation four-fold when compared with placebo. The 
reduction in daily smoking consumption in patients treated with varenicline was significantly 
greater than in people in the placebo control groups. There was no clear evidence that 
varenicline was associated with an increased risk of neuropsychiatric or other adverse events 
in people with severe mental illness, compared with placebo. Future studies with larger 
sample sizes are needed to provide more evidence of the safety and long-term efficacy of 
varenicline in smoking cessation and reduction in patients with severe mental illness.   
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Figure 1 The PRISMA flow chart of included and excluded studies 
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Figure 2 Varenicline versus placebo: smoking cessation at the end of the trial 
 
Figure 3 Varenicline versus placebo: smoking reduction at the end of treatment 
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Figure 4 Forest plots: suicidal ideation, depressed mood and anxiety 
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Table 1 Characteristics of included studies 
Authors Study design 
and sample Population Interventions Country Outcome: smoking cessation 
Chengappa 
et al., 2014 RCT, N=60 
Clinically stable adult patients aged 
18 to 65 with DSM-IV bipolar 
disorder who smoked at least 10 
cigarettes per day.  They were willing 
to quit smoking in the next 30 days 
and no use of NRT, BUP or 
nonpharmacologic treatments for 
smoking cessation in the 3 months 
prior to the study enrolment.  
1. Varenicline tablet of 0.5 mg strength 
orally at bedtime for day 1-3, increased to 
1.0 mg for day 4-7, then 2 mg/day for week 
2-12.  
2. Placebo for 12 weeks. 
Both groups received 15 minutes smoking 
cessation counselling for each visit.     
US 
7-day point prevalence of self
reported no smoking verified 
by expired carbon monoxide 
level < 10 ppm at 12 and 24 
weeks.  
Fatemi, 
2013 RCT, N=24 
Clinically stable adults diagnosed 
with schizophrenia or schizoaffective 
disorder, who smoked at least 10 
cigarettes per day and expressed a 
motivation to either quit or reduce 
smoking. Subjects did not use other 
nicotine products (i.e., smokeless 
tobacco), and were not currently 
taking bupropion or varenicline. 
1. Varenicline 1 mg twice a day for 12 
weeks.  
2. Bupropion SR 150 mg twice a day for 12 
weeks.  
3. Placebo twice a day for 12 weeks.  
All participants received 20 minutes anti-
smoking counselling at each visit.  
US 
The proposed smoking 
cessation measure was 
abstinence as measured by sel
report and verified 
biochemically through exhale
carbon monoxide (CO), as we
as serum and urine levels of 
nicotine and its metabolite 
cotinine. However, the result 
ZDVQ¶WUHSRUWHGLQWKHSDSHU 
Hong et 
al., 2011 
Double-blind, 
parallel-
groups 
design, 
N=69 
(N=43 were 
smokers) 
Patients aged 18 to 60 with 
schizophrenia or schizoaffective 
disorder, had received antipsychotic 
medication, and were clinically stable 
for 4 weeks or longer.  
1.Varenicline, 0.5 mg daily for 1 week then 
0.5 mg twice daily for 7 weeks.  
2. Placebo for 8 weeks. 
  
US 
The study reported number of
quitters but did not mention 
how they defined smoking 
cessation in the methods.  
Meszaros  
et al., 2013 RCT, N=10 
Clinically stable outpatients with 
schizophrenia or schizoaffective 
disorder and concurrent alcohol and 
nicotine dependence. Smoked at least 
20 cigarettes per day and drank at 
least 7 standard alcoholic drinks over 
the 7 days before intake.  
1. Varenicline, 0.5 mg daily for day 1 to 3, 
then 0.5 mg twice daily for day 4 to 7 then 
1 mg twice daily for week 2 to 8.  
2. Placebo. 
US Not reported. 
Shim et al., 
2012 
RCT, N=120 
(60 smokers 
and 60 non-
smokers)  
Clinically stable outpatients aged 18 
to 60 with chronic schizophrenia. 
PANSS <=75, CPD > 10. 
1.Varenicline 0.5 mg daily for day 1 to 3, 
then 0.5 mg twice daily for day 4 to 7 then 
1 mg twice daily for week 2 to 8.  
2. Placebo for 8 weeks. 
Korea No smokers in either treatmengroup quit smoking entirely.  
KDYHQ¶WEHHQUHSRUWHGLQ
Weiner et 
al., 2011 RCT, N=9 
Stable schizophrenia or 
schizoaffective disorder outpatients. 
Regular smokers (CPD >=10, 
smoking at least one year and FTND 
>=4). 
1. Varenicline 1 mg twice daily for 12 
weeks. 
2. Placebo for 12 weeks. 
Both groups received individual smoking 
cessation counselling. 
US 
 
Smoking cessation (defined a
expired CO<10 ppm at each o
the last 4 visits at week 12. 
Change in CO from baseline t
end of study and changes in 
positive symptoms. 
  
Williams et 
al., 2012 RCT, N=127 
Clinically stable schizophrenia or 
schizoaffective disorder outpatients 
(PANSS<70) aged 18-75 years who 
smoked at least 15 cigarettes per day, 
and willing to quit in 30 days.  
1. Varenicline 0.5 mg tablet for day 1-3, 
increased to 1.0 mg for day 4-7, then 2 
mg/day for weeks 2-12. 
 2. Placebo.  
All patients received weekly clinic visits 
which included smoking cessation 
counselling. 
US and 
Canada 
7-day abstinence at week-12 
and week-24 validated by 
carbon CO.  
Wu et al., 
2012 RCT, N=5 
Clinically stable adult outpatients with 
a SCID-derived DSM-IV diagnosis of 
bipolar I or II disorder, who smoked 
at least 10 cigarettes per day. 
1. Varenicline (1 mg twice a day) for 10 
weeks. 
2. Placebo for 10 weeks.                    
All patients received weekly smoking 
cessation counselling. 
US 
Biochemically verified 
smoking abstinence at trial 
endpoint by expired breath 
carbon monoxide levels (<= 1
ppm). Reduction measured by
changes in cigar per day. But 
all of the participants in the 
control group dropped out at 
week 3.  
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Table 2 Adverse effects of varenicline in people with SMI  
 Varenicline  Placebo Pooled Relative Risk 95% CI 
Adverse Event (n=158) (n=114)    
Gastrointestinal disorders       
Diarrhoea 9 5 1.12  ( 0.36-3.52 ) 
Constipation 12 13 0.90  ( 0.43-1.85 ) 
Dry mouth 20 15 1.27  ( 0.66-2.46 ) 
Flatulence 20 22 0.88  ( 0.54-1.44 ) 
Vomiting 17 11 1.12  ( 0.36-3.45 ) 
Nausea 46 25 1.35  ( 0.89-2.06 ) 
Dyspepsia (heartburn) 10 11 0.89  ( 0.41-1.95 ) 
Abdominal pain 25 18 1.16  ( 0.56-2.4 ) 
Gastroesophageal reflux 7 2 3.27  ( 0.74-14.49 ) 
Psychiatric disorders 
     
  
Depressed mood 13 6 1.45  ( 0.45-4.64 ) 
Anxiety 13 14 0.77  ( 0.28-2.17 ) 
Suicidal ideation 9 5 1.06  ( 0.4-2.82 ) 
Mood swings 2 1 1.87  ( 0.17-19.55 ) 
Insomnia 31 21 1.25  ( 0.74-2.11 ) 
Abnormal dreams 27 24 0.79  ( 0.24-2.65 ) 
Nightmare 7 8 0.87  ( 0.35-2.14 ) 
Euphoria 4 10 0.40  ( 0.14-1.14 ) 
Hypertension   1 2 0.50  ( 0.06-3.91 ) 
Nervous system disorders 
    
Somnolence 16 11 1.43  ( 0.77-2.67 ) 
Headache 23 30 0.62  ( 0.36-1.08 ) 
Dizziness 10 9 1.08  ( 0.48-2.39 ) 
Bad taste 4 2 1.87  ( 0.37-9.46 ) 
Musculoskeletal/connective tissue disorders 
    
Artralgia/pain 5 5 0.65  ( 0.2-2.17 ) 
General disorders 
    
Fatigue/lethargy 26 17 1.35  ( 0.8-2.27 ) 
Asthenia/weakness 1 4 0.23  ( 0.03-1.97 ) 
Irritability 7 6 0.75  ( 0.29-1.92 ) 
Respiratory disorders 
    
Rhinorrhea/runny nose 6 6 0.94  ( 0.34-2.57 ) 
Shortness of breath 4 1 3.74  ( 0.44-31.55 ) 
Skin manifestations 
    
Rash 3 2 1.40  ( 0.25-7.81 ) 
Metabolism and nutrition 
    
Increased appetite 17 12 1.37  ( 0.72-2.64 ) 
Decreased appetite 16 15 0.96  ( 0.51-1.82 ) 
Weight gain 2 2 0.94  ( 0.14-6.21 ) 
Weight loss 2 1 1.87  ( 0.18-19.55 ) 
Renal and urinary disorder 
    
Urinary tract infection 2 0 4.69  ( 0.23-93.7 ) 
Infections and infestations 
    
Upper respiratory tract infection 6 1 3.07  ( 0.38-24.7 ) 
 
 
 
